Journal of Nutrition OpenSOurce Diets- www.ResearchDiets.com

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by King, R. A.
Right arrow Articles by Head, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by King, R. A.
Right arrow Articles by Head, R. J.

Absorption and Excretion of the Soy Isoflavone Genistein in Rats1

Roger A. King2, Jessica L. Broadbent* and Richard J. Head*

CSIRO Division of Human Nutrition, Adelaide, South Australia 5000 * Department of Clinical and Experimental Pharmacology, University of Adelaide, South Australia 5000

Rodent models have been used to study the anticarcinogenic properties of the soy isoflavones, particularly genistein, but there is little information regarding the pharmacokinetics of the absorption and excretion of genistein. In this study, rats were given a single oral dose of genistein (20 mg/kg body weight) or an equivalent dose of its glycone forms, as an isoflavone-rich soy extract. Concentrations of genistein were measured in plasma, urine and feces at intervals up to 48 h after dosing. Plasma genistein concentration at 2 h after dosing was 11.0 ± 2.3 µmol/L in genistein-treated rats compared with 4.93 ± 0.22 µmol/L (P = 0.025) in soy extract-treated rats, but there were no significant differences at 8 h and later times. The mean urinary excretion rate during the first 2 h after dosing was more than 10 times higher in the genistein group compared with the soy extract group (0.27 ± 0.08 µmol/h and 0.020 ± 0.011 µmol/h, respectively, P = 0.017) but the percentage of dose recovered in urine over 48 h was not different between groups (19.9 ± 2.4% genistein treated; 17.5 ± 1.1% soy extract treated). There were no significant differences between groups in the recovery of genistein in feces (21.9 ± 2.8% and 21.1 ± 2.5% of dose, respectively). Only 6.1 ± 0.9% of the daidzein from the soy extract was recovered in the feces. The results suggest that the extent of absorption of genistein is similar for the glycone and aglycone forms. Although higher initial plasma concentrations may be achieved with the aglycone, similar long-term concentrations exist for both forms of isoflavone.


KEY WORDS: • genistein • daidzein • pharmacokinetics • rats • soy

1 The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

2 To whom correspondence should be addressed.

Manuscript received 10 July 1995. Revision accepted 16 August 1995.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
T. L. Guo, R. P. Chi, D. M. Hernandez, W. Auttachoat, and J. F. Zheng
Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein
Carcinogenesis, December 1, 2007; 28(12): 2560 - 2566.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
J. K. Prasain, J. Xu, M. Kirk, M. Smith Johnson, J. Sfakianos, and S. Barnes
Differential Biliary Excretion of Genistein Metabolites Following Intraduodenal and Intravenous Infusion of Genistin in Female Rats
J. Nutr., December 1, 2006; 136(12): 2975 - 2979.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. W. J. Wang, J. Chen, X. Jia, V. H. Tam, and M. Hu
Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties
Drug Metab. Dispos., November 1, 2006; 34(11): 1837 - 1848.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
L. Zubik and M. Meydani
Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women
Am. J. Clinical Nutrition, June 1, 2003; 77(6): 1459 - 1465.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
V. Crespy, C. Morand, C. Besson, N. Cotelle, H. Vezin, C. Demigne, and C. Remesy
The splanchnic metabolism of flavonoids highly differed according to the nature of the compound
Am J Physiol Gastrointest Liver Physiol, June 1, 2003; 284(6): G980 - G988.
[Abstract] [Full Text] [PDF]


Home page
International Journal of ToxicologyHome page
W. Slikker Jr., A. C. Scallet, D. R. Doerge, and S. A. Ferguson
Gender-Based Differences in Rats after Chronic Dietary Exposure to Genistein
International Journal of Toxicology, May 1, 2001; 20(3): 175 - 179.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 1996 by American Society for Nutrition